Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $55.25 | Total: $276.25 |
| 1 | 10 | $46.80 | Total: $468.00 |
| 1 | 25 | $39.65 | Total: $991.25 |
| 1 | 50 | $33.80 | Total: $1,690.00 |
| 1 | 100 | $29.25 | Total: $2,925.00 |
Overview
Enloplatin is a carboplatin analog that has a partial role in advanced ovarian cancer.
Chemical Properties
| Molecular Formula | C13H22N2O5Pt |
| Molecular Weight | 481.4 |
| CAS Numbers | 111523-41-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1C2(C(=O)[O-][Pt+2]3([O-]1)[NH2]CC4(C[NH2]3)CCOCC4)CCC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Kudelka AP, et al. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma. Anticancer Drugs. 1997;8[7] 649-656.